Does the media favor KROS or DSGN?

In the previous week, Design Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Design Therapeutics and 2 mentions for Keros Therapeutics. Design Therapeutics' average media sentiment score of 1.56 beat Keros Therapeutics' score of 0.94 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor KROS or EVMN?

In the previous week, Evommune had 11 more articles in the media than Keros Therapeutics. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.94 beat Evommune's score of -0.53 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media refer more to KROS or PHAT?

In the previous week, Keros Therapeutics and Keros Therapeutics both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 0.94 beat Phathom Pharmaceuticals' score of 0.63 indicating that Keros Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KROS or ESPR?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Keros Therapeutics. Esperion Therapeutics' average media sentiment score of 1.42 beat Keros Therapeutics' score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, VOR or KROS?

Keros Therapeutics has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Keros Therapeutics $244.06M 0.87 $87.01M -$3.01 N/A

Does the media prefer VOR or KROS?

In the previous week, Vor Biopharma had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Keros Therapeutics. Vor Biopharma's average media sentiment score of 0.94 equaled Keros Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Keros Therapeutics (KROS) Competitors

$10.70 -0.23 (-2.10%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$10.68 -0.01 (-0.14%)

As of 06/30/2026 06:32 PM Eastern

Compare

KROS vs. DSGN, EVMN, PHAT, ESPR, and VOR

Should you buy Keros Therapeutics stock or one of its competitors? MarketBeat compares Keros Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keros Therapeutics include Design Therapeutics (DSGN), Evommune (EVMN), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

How does Keros Therapeutics compare to Design Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Keros Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Keros Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

In the previous week, Design Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Design Therapeutics and 2 mentions for Keros Therapeutics. Design Therapeutics' average media sentiment score of 1.56 beat Keros Therapeutics' score of 0.94 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Keros Therapeutics presently has a consensus target price of $20.40, indicating a potential upside of 90.65%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 14.03%. Given Keros Therapeutics' higher possible upside, research analysts clearly believe Keros Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Design Therapeutics	N/A	-33.07%	-31.29%

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Keros Therapeutics and Design Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Evommune?

Keros Therapeutics (NASDAQ:KROS) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Evommune had 11 more articles in the media than Keros Therapeutics. MarketBeat recorded 13 mentions for Evommune and 2 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.94 beat Evommune's score of -0.53 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Evommune has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Evommune's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Evommune	N/A	N/A	N/A

71.6% of Keros Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Keros Therapeutics has higher revenue and earnings than Evommune. Keros Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A
Evommune	$13M	36.79	-$68.87M	-$9.50	N/A

Keros Therapeutics currently has a consensus target price of $20.40, indicating a potential upside of 90.65%. Evommune has a consensus target price of $45.63, indicating a potential upside of 243.59%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

Summary

Evommune beats Keros Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Phathom Pharmaceuticals?

Keros Therapeutics (NASDAQ:KROS) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Keros Therapeutics and Keros Therapeutics both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 0.94 beat Phathom Pharmaceuticals' score of 0.63 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phathom Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Keros Therapeutics' net margin of -256.60%. Phathom Pharmaceuticals' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Keros Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Keros Therapeutics presently has a consensus price target of $20.40, indicating a potential upside of 90.65%. Phathom Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 125.81%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Keros Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A
Phathom Pharmaceuticals	$175.11M	4.94	-$221.25M	-$2.12	N/A

Summary

Phathom Pharmaceuticals beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Esperion Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Keros Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Keros Therapeutics' net margin of -256.60%. Esperion Therapeutics' return on equity of -0.14% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-17.04%	-15.84%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Keros Therapeutics currently has a consensus target price of $20.40, indicating a potential upside of 90.65%. Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 75.32%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Keros Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 22.9% of Keros Therapeutics shares are owned by insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Keros Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

In the previous week, Esperion Therapeutics had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Esperion Therapeutics and 2 mentions for Keros Therapeutics. Esperion Therapeutics' average media sentiment score of 1.42 beat Keros Therapeutics' score of 0.94 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Esperion Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Esperion Therapeutics beats Keros Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Keros Therapeutics (NASDAQ:KROS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vor Biopharma had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Keros Therapeutics. Vor Biopharma's average media sentiment score of 0.94 equaled Keros Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Keros Therapeutics has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Keros Therapeutics	$244.06M	0.87	$87.01M	-$3.01	N/A

Vor Biopharma has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Vor Biopharma has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Vor Biopharma's return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Vor Biopharma currently has a consensus price target of $42.25, suggesting a potential upside of 129.49%. Keros Therapeutics has a consensus price target of $20.40, suggesting a potential upside of 90.65%. Given Vor Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Vor Biopharma is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Vor Biopharma beats Keros Therapeutics on 10 of the 12 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$216.32M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-3.55	20.90	27.25	24.87
Price / Sales	0.87	341.80	540.68	102.84
Price / Cash	2.41	143.77	48.53	58.59
Price / Book	0.69	8.75	11.01	6.54
Net Income	$87.01M	$23.81M	$3.57B	$336.70M
7 Day Performance	-2.10%	3.60%	2.31%	2.88%
1 Month Performance	-1.83%	3.72%	1.39%	0.64%
1 Year Performance	-19.79%	68.80%	36.71%	31.34%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.207 of 5 stars	$10.70 -2.1%	$20.40 +90.7%	-19.9%	$216.32M	$244.06M	N/A	100
DSGN Design Therapeutics	2.0502 of 5 stars	$13.44 -2.5%	$16.50 +22.8%	+329.4%	$860.66M	N/A	N/A	40	News Coverage Positive News
EVMN Evommune	2.23 of 5 stars	$24.00 +1.9%	$49.25 +105.2%	N/A	$848.58M	$10M	N/A	45	News Coverage Analyst Downgrade
PHAT Phathom Pharmaceuticals	2.0999 of 5 stars	$10.34 -2.5%	$24.50 +136.9%	+13.1%	$846.21M	$175.11M	N/A	110
ESPR Esperion Therapeutics	2.7145 of 5 stars	$3.15 flat	$5.54 +75.9%	+221.0%	$811.73M	$403.14M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. DSGN, EVMN, PHAT, ESPR, and VOR

How does Keros Therapeutics compare to Design Therapeutics?

Summary

How does Keros Therapeutics compare to Evommune?

Summary

How does Keros Therapeutics compare to Phathom Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Esperion Therapeutics?

Summary

How does Keros Therapeutics compare to Vor Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. DSGN, EVMN, PHAT, ESPR, and VOR

How does Keros Therapeutics compare to Design Therapeutics?

Which has higher earnings and valuation, KROS or DSGN?

Which has more volatility and risk, KROS or DSGN?

Does the media favor KROS or DSGN?

Do analysts prefer KROS or DSGN?

Is KROS or DSGN more profitable?

Do institutionals & insiders have more ownership in KROS or DSGN?

Summary

How does Keros Therapeutics compare to Evommune?

Does the media favor KROS or EVMN?

Is KROS or EVMN more profitable?

Do insiders & institutionals have more ownership in KROS or EVMN?

Which has preferable valuation and earnings, KROS or EVMN?

Do analysts prefer KROS or EVMN?

Summary

How does Keros Therapeutics compare to Phathom Pharmaceuticals?

Does the media refer more to KROS or PHAT?

Do insiders and institutionals have more ownership in KROS or PHAT?

Is KROS or PHAT more profitable?

Which has more risk and volatility, KROS or PHAT?

Do analysts prefer KROS or PHAT?

Which has stronger earnings & valuation, KROS or PHAT?

Summary

How does Keros Therapeutics compare to Esperion Therapeutics?

Which has better valuation & earnings, KROS or ESPR?

Is KROS or ESPR more profitable?

Do analysts prefer KROS or ESPR?

Do institutionals & insiders have more ownership in KROS or ESPR?

Which has more volatility and risk, KROS or ESPR?

Does the media refer more to KROS or ESPR?

Summary

How does Keros Therapeutics compare to Vor Biopharma?

Do institutionals and insiders hold more shares of VOR or KROS?

Does the media prefer VOR or KROS?

Which has preferable valuation & earnings, VOR or KROS?

Which has more volatility and risk, VOR or KROS?

Is VOR or KROS more profitable?

Do analysts recommend VOR or KROS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools